Sutro Biopharma Hits New 52-Week High of $21.40, Soars 453%

Sutro Biopharma, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 21.40 on March 4, 2026. This achievement marks a remarkable performance over the past year, with the stock soaring by 453.51%, significantly outpacing the S&P 500's growth of 17.36%. The company's market capitalization stands at USD 302 million, reflecting its position within the microcap category. Despite being loss-making, Sutro Biopharma showcases an impressive return on equity of 192.22%, indicating effective management of its equity base. However, the company does not offer a dividend, and its debt-to-equity ratio is reported at -0.58, suggesting a unique financial structure. The stock's journey from a 52-week low of USD 0.80 to its current high underscores the volatility and potential within the biotechnology space. As Sutro Biopharma continues to navigate its operational landscape, this new price point highlights its recent performance and market dynamics.